Twenty Four Month Extension Study of BA058-05-003



Status:Completed
Conditions:Osteoporosis, Postmenopausal Syndrome
Therapuetic Areas:Endocrinology, Rheumatology
Healthy:No
Age Range:Any
Updated:4/14/2017
Start Date:October 2012
End Date:October 2016

Use our guide to learn which trials are right for you!

An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

The purpose of this study is to provide 24 months of standard of care data on subjects
previously enrolled in study BA058-05-003.


Inclusion Criteria:

1. The subject was enrolled, randomized to either the BA058 (abaloparatide) or placebo
arm, and successfully completed Study BA058-05-003.

Exclusion Criteria:

1. Were withdrawn from Study BA058-05-003 for any reason.

2. Experienced a treatment-related SAE during Study BA058-05-003.
We found this trial at
5
sites
2197
mi
from 91732
NMiami, FL
Click here to add this to my saved trials
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
2277
mi
from 91732
Bethesda, MD
Click here to add this to my saved trials
6113
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
812
mi
from 91732
Lakewood, CO
Click here to add this to my saved trials